2021medRxivOpen access

Comparison of Saliva and Mid-Turbinate Swabs for Detection of COVID-19

Jianyu Lai, Jennifer German, Filbert Hong, Sheldon Tai, Kathleen McPhaul, Donald K. Milton

Open full text 12 citations

Abstract

Abstract Background Saliva is an attractive sample for detecting SARS-CoV-2. However, contradictory reports exist concerning the sensitivity of saliva versus nasal swabs. Methods We followed close contacts of COVID-19 cases for up to 14 days from last exposure and collected self-reported symptoms, mid-turbinate swabs (MTS), and saliva every two or three days. Ct values, viral load, and frequency of viral detection by MTS and saliva were compared. Results 58 contacts provided 200 saliva-MTS pairs; 14 contacts (13 with symptoms) had one or more positive samples. Saliva and MTS had similar rates of viral detection (p=0.78) and substantial agreement (κ=0.83). However, sensitivity varied significantly with time since symptom onset. Early on (days -3 to 2), saliva had 12 times (95%CI: 1.2, 130) greater likelihood of viral detection and 3.2 times (95% CI: 2.8, 3.8) higher RNA copy numbers compared to MTS. After day 2 post-symptoms, there was a non-significant trend toward greater sensitivity using MTS. Conclusion Saliva and MTS demonstrated high agreement making saliva a suitable alternative to MTS for COVID-19 detection. Saliva was more sensitive early in the infection when transmission is most likely to occur, suggesting that it may be a superior and cost-effective screening tool for COVID-19.

Open-access reader

About this research paper

What this paper is about

Abstract Background Saliva is an attractive sample for detecting SARS-CoV-2. However, contradictory reports exist concerning the sensitivity of saliva versus nasal swabs. Methods We followed close contacts of COVID-19 cases for up to 14 days from last exposure and collected self-reported symptoms, mid-turbinate swabs (MTS), and saliva every two or three days. Ct values, viral load, and frequency of viral detection by MTS and saliva were compared. Results 58 contacts provided 200 saliva-MTS pairs; 14 contacts (13 with symptoms) had one or more positive samples. Saliva and MTS had similar rates of viral detection (p=0.78) and substantial agreement (κ=0.83). However, sensitivity varied significantly with time since symptom onset. Early on (days -3 to 2), saliva had 12 times (95%CI: 1.2, 130) greater likelihood of viral detection and 3.2 times (95% CI: 2.8, 3.8) higher RNA copy numbers compared to MTS. After day 2 post-symptoms, there was a non-significant trend toward greater sensitivity using MTS. Conclusion Saliva and MTS demonstrated high agreement making saliva a suitable alternative to MTS for COVID-19 detection. Saliva was more sensitive early in the infection when transmission is most likely to occur, suggesting that it may be a superior and cost-effective screening tool for COVID-19.

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract Background Saliva is an attractive sample for detecting SARS-CoV-2. However, contradictory reports exist concerning the sensitivity of saliva versus nasal swabs. Methods We followed close contacts of COVID-19 cases for up to 14 days from last exposure and collected self-reported symptoms, mid-turbinate swabs (MTS), and saliva every two or three days. Ct values, viral load, and frequency of viral detection by MTS and saliva were compared. Results 58 contacts provided 200 saliva-MTS pairs; 14 contacts (13 with symptoms) had one or more positive samples. Saliva and MTS had similar rates of viral detection (p=0.78) and substantial agreement (κ=0.83). However, sensitivity varied significantly with time since symptom onset. Early on (days -3 to 2), saliva had 12 times (95%CI: 1.2, 130) greater likelihood of viral detection and 3.2 times (95% CI: 2.8, 3.8) higher RNA copy numbers compared to MTS. After day 2 post-symptoms, there was a non-significant trend toward greater sensitivity using MTS. Conclusion Saliva and MTS demonstrated high agreement making saliva a suitable alternative to MTS for COVID-19 detection. Saliva was more sensitive early in the infection when transmission is most likely to occur, suggesting that it may be a superior and cost-effective screening tool for COVID-19.

Key concepts: Saliva, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Medicine, Viral load, Virology, Virus, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Comparison of Saliva and Mid-Turbinate Swabs for Detection of COVID-19 — Research Paper | ScholarLens